Drugs / Mitoglitazone
Mitoglitazone
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01374438 | Jul 2011 → Mar 2013 | Alzheimer disease | Metabolic Solutions Development Company | Completed | No outcome recorded |
| Phase 2 | NCT01103414 | Sep 2010 → Nov 2011 | type 2 diabetes mellitus | Metabolic Solutions Development Company | Completed | No outcome recorded |
| Phase 2 | NCT00760578 | Sep 2008 → Jan 2009 | type 2 diabetes mellitus | Metabolic Solutions Development Company | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mitoglitazone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01103414 ↗ |
| Known as | CAY-10415 | ChEMBL registry synonym — accepted as the source's own label CHEMBL146624 ↗ |
| Known as | J730.386F | ChEMBL registry synonym — accepted as the source's own label CHEMBL146624 ↗ |
| Known as | MSD-9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL146624 ↗ |
| Known as | MSDC-0160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00760578 ↗ |
| Known as | PNU-91325 | ChEMBL registry synonym — accepted as the source's own label CHEMBL146624 ↗ |
| Known as | U-91325 | ChEMBL registry synonym — accepted as the source's own label CHEMBL146624 ↗ |
| Modality | Small molecule | — CHEMBL146624 ↗ |
| Route | Oral | “Once daily, oral” NCT00760578 ↗ |